Elgin-Oxford measles cases surge for second straight week
Southwestern Public Health, the health unit that oversees Oxford and Elgin Counties and St. Thomas, is reporting 65 news measles cases since April 24 as of Thursday. The 65 cases is the largest seven-day increase since the health unit's epidemiology team began tracking weekly case counts on Feb. 27, health officials said. As of Feb. 27, the health unit had recorded 85 measles cases dating back to October 2024 when the outbreak began.
During a virtual news conference on Thursday, Ninh Tran, medical officer for Southwestern Public Health, said the past week's measles case count was 'certainly a noticeable rise,' and attributed the cases to a cluster of unvaccinated individuals.
'This sharp rise in cases may be concerning to the community,' Tran said. 'However, the majority of these cases are part of a group of cases we are investigating that are linked to one another.'
Tran continued: 'This is good example of how quickly measles can spread in groups where there are unvaccinated individuals. It is not uncommon to have increased number of cases reported after exposures in large households between siblings and other family members.'
The increase in measles cases marks the second straight week the disease has spiked after a drop in cases. The health unit had recorded its lowest seven-day count with 15 cases between April 10 and April 17, followed by 28 cases between April 17 and April 24.
Southwestern Public Health has updated its recorded measles case count from seven to 15 cases between April 10 and April 17. However, 15 cases remains the lowest seven-day case count since the health unit began tracking weekly figures in February.
Thursday's report brings the total measles cases recorded by Southwestern Public Health to 451, accounting for about 35 per cent of the province's 1,243 cases Public Health Ontario was reporting as of April 29.
There's a slight discrepancy between Public Health Ontario and Southwestern Public Health because the provincial agency records its data a day earlier.
Southwestern Public Health's rate of cases per 100,000 people is 181 while the overall rate in Ontario is 7.9 cases per 100,000 people, Public Health Ontario said in its updated epidemiological report released on Thursday.
The province's numbers jumped by 223 cases between April 23 and April 29, Public Health Ontario said in its report.
'The increase in the number of outbreak cases and the geographic spread in recent weeks is due to continued exposures and transmission among individuals who have not been immunized,' the report said.
Southwestern, Grand Erie (Brant, Norfolk and Haldimand), Huron Perth and Chatham-Kent account for 71 per cent of Ontario's cases.
As of Thursday, Middlesex-London Health Unit has reported 28 cases, officials from the public health office stated, noting most of the cases were 'clusters among unvaccinated individuals.'
Tran said about 7.8 per cent of the cases reported by Southwest Public Health have resulted in hospitalization.
'I do want to highlight that measles can result in complications . . . including hospitalizations,' Tran said.
Measles symptoms include a red rash, fever, cough, runny nose, upper respiratory symptoms, red eyes and fatigue. Serious complications such as pneumonia, encephalitis, blindness and death are possible.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
a day ago
- Hamilton Spectator
Justin Timberlake reveals ‘relentlessly debilitating' Lyme disease symptoms — Do you live in Ontario's high risk areas?
Justin Timberlake has Lyme disease. The famous pop star confirmed his battle with 'relentlessly debilitating' Lyme disease symptoms in an Instagram post Thursday . 'When I first got the diagnosis I was shocked for sure,' he wrote. 'But, at least I could understand why I would be onstage and in a massive amount of nerve pain or, just feeling crazy fatigue or sickness.' Timberlake faced criticism for recent performances in Europe over what fans described as low-energy shows. It appears Lyme disease may be to blame. 'I was faced with a personal decision. Stop touring? Or, keep going and figure it out,' Timberlake wrote on Instagram. 'I decided the joy that performing brings me far outweighs the fleeting stress my body was feeling. I'm so glad I kept going.' Timberlake just completed his 'Forget Tomorrow World Tour' in Istanbul, Turkey on Tuesday. The tour started in Vancouver last April. A post shared by Justin Timberlake (@justintimberlake) Notable Canadian celebrities who have shared their diagnosis with Lyme disease include Avril Lavigne, Justin Bieber and Shania Twain. The blacklegged tick is known to transmit four tick-borne diseases — anaplasmosis, babesiosis, Lyme disease and Powassan virus — that are listed as Diseases of Public Health Significance by Public Health Ontario (PHO). Lyme disease occurs in stages. Symptoms can vary from person to person after being bitten by an infected blacklegged tick or western blacklegged tick. Signs and symptoms of each stage can overlap. 'In some people, Lyme disease may present in a later stage without a history of prior signs or symptoms,' the Public Health Agency of Canada (PHAC) explains. Early signs and symptoms of Lyme disease can manifest as: The erythema migrans rash is the most commonly reported sign of Lyme disease. PHAC explains it's an expanding skin rash that usually starts at the site of the tick bite slowly expanding over several days. The rash can be circular or oval-shaped, looking like a target or bull's eye. It can go unnoticed if it's on dark skin or a part of the body that's hard to see. PHAC says some people might not develop a rash at all. The bull's-eye shape of this rash is a clear sign of Lyme disease. Later symptoms of Lyme disease can appear days to months after an infected tick bite and might manifest as: In very rare cases, death can occur due to the complications involving an infection of the heart. Lyme disease is a growing concern in Canada particularly in southern Ontario, which is considered one of a few hot spots for ticks. Tick populations continue to climb in Ontario, as well as other parts of Canada. This year is expected to follow the trend . The Public Health Agency of Canada has a tool where you can type in your postal code and it will tell you if you're located in a risk area for Lyme disease. Some risk areas include spots in Windsor, Whitby, Waterloo, Uxbridge, The Blue Mountains, Tay Valley, St. Catharines, Smiths Falls, Scugog, Richmond Hill, Rideau Lakes, Renfrew, Prince Edward County, Port Hope, Perth, Peel, Ottawa, Oshawa, Orillia, Oakville, Niagara Falls, Newmarket, Mississauga, Milton, Markham, Hamilton, Clarington, Caledon, Burlington, Brampton, Kawartha Lakes, Barrie, Ajax and more. Map of five areas known for risk to tick exposure in Canada. The number of human reported Lyme disease cases in Canada in 2024 was 5,239, according to preliminary data from the PHAC. That's a jump from the 4,785 cases reported in 2023 and 2,525 in 2022. For a matter of perspective, only 144 cases were reported in 2009. Out of the 4,785 cases in 2023, 1,865 were reported in Ontario, according to Public Health Ontario data. In Canada, Lyme disease is caused by a bacterium called Borrelia burgdorferi, which is spread through the bite of infected blacklegged ticks — also known as deer ticks — and western blacklegged ticks, according to the PHAC. The blacklegged tick, or deer tick as it is sometimes called, is the most common carrier of Lyme disease. Despite the established risk areas for ticks, Public Health Ontario said it's important for people to know they could encounter an infected blacklegged tick almost anywhere in Ontario , as blacklegged ticks feed on and are transported by migratory birds. Species of ticks can be found in most parts of Ontario — clustering along the north shores of Lake Erie, Lake Ontario and the St. Lawrence River, according to PHO. This map depicts the estimated risk areas for Lyme disease in Ontario in 2024. Risk areas for Lyme disease in southern Ontario can be found along the north shores of Lake Erie and Lake Ontario and on the south shore of Lake Huron, according to PHAC . In southeastern Ontario, risk areas can be found around Kingston in the St. Lawrence valley, extending northeast toward Ottawa. PHO data shows Lyme disease was reported in all but one health unit region in 2023. The highest concentration of reported cases in Ontario in 2013 was in the Ontario health unit catchment areas of Hastings Prince Edward Public Health and Kingston, Frontenac, Lennox & Addington Public Health. In 2023, 84 people in Ontario were hospitalized for Lyme disease. PHO shows Lyme rates have been climbing for the last 10 years. Climate change is contributing to the spread of blacklegged ticks to new areas in Canada. Southern, western and southeastern Ontario, parts of Manitoba, southern Quebec and the Maritime provinces are known to be risk areas for ticks and Lyme disease exposure. Map of five areas known for risk to tick exposure in Canada. Lyme disease and other tick-borne illnesses can cause serious medical issues. Here are some proactive measures to take to avoid getting bitten by a tick. For more information on ticks , visit the Public Health Agency of Canada's website. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Fast Company
a day ago
- Fast Company
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last year, the High Court ruled that one of Moderna's patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech's Comirnaty vaccine had infringed it, meaning Moderna is entitled to damages in relation to sales after March 2022. The High Court also ruled that the other Moderna patent under challenge in the case was invalid. Moderna was refused permission to appeal against that decision. But Pfizer and BioNTech were granted permission to appeal in an attempt to try and invalidate Moderna's second patent and appealed earlier this month, arguing Moderna's developments of mRNA technology were obvious developments of previous work, rendering the patent invalid. Judge Richard Arnold, however, rejected Pfizer and BioNTech's appeal. Pfizer and BioNTech said in a joint statement that the decision 'does not change our unwavering stance that this patent is invalid' and the companies will seek to appeal. 'This decision has no immediate impact on Pfizer and BioNTech or Comirnaty,' the companies added. Moderna did not immediately respond to a request for comment. Friday's decision in the latest ruling in the legal dispute between the two sides over their competing vaccines, which helped save millions of lives during the pandemic. The companies have also been involved in proceedings in Germany – where a court ruled in Moderna's favour in March – the United States Patent Office, which held that two Moderna COVID-19 vaccine patents were invalid, and elsewhere.
Medscape
a day ago
- Medscape
Chemotherapy Linked to Brain Atrophy in Breast
Patients with breast cancer who undergo chemotherapy may face an increased risk for brain atrophy and cognitive decline, new findings from a pilot study suggested. Memory problems in patients with cancer may not stem solely from stress or anxiety related to their diagnosis but could reflect underlying changes in brain structure, study investigator Paul Edison, PhD, MPhil, professor of neuroscience and clinical professor of neurology at Imperial College London, London, England, told Medscape Medical News . While the findings suggest that chemotherapy may contribute to neuronal damage, the researchers noted that many aspects of the relationship between treatment and brain changes remain unclear. Edison highlighted three key areas that require further investigation — uncovering the mechanisms driving brain atrophy, determining the proportion of patients affected, and identifying effective prevention strategies. Another investigator on the study, Laura Kenny, MD, PhD, associate professor and consultant medical oncologist at Imperial College London, noted that the issue has received limited attention to date but expressed hope that the findings will raise awareness and encourage further research, given its clinical importance. The findings were presented on July 29 at the Alzheimer's Association International Conference (AAIC) 2025. Investigating Cognitive Impact Advances in chemotherapeutic agents have improved survival rates in patients with cancer. However, challenges persist regarding the long-term impact of these drugs. Chemotherapy-associated cognitive impairment, often referred to as 'brain fog' or 'chemobrain,' affects approximately one third of patients with breast cancer following treatment. While cognitive decline resolves within 12 months for some patients, others experience persistent effects that may elevate the risk for neurodegenerative conditions, Edison explained. To evaluate the impact of chemotherapy on the brain, investigators studied 328 women with nonmetastatic breast cancer who had undergone chemotherapy within the past 12 months. Patients received either anthracycline — a drug derived from the Streptomyces peucetius bacterium — or taxanes such as docetaxel and paclitaxel, both commonly used in breast cancer treatment, or a combination of these agents. In addition, some patients may also have had hormone therapy at some point during treatment, said Kenny. Participants completed neurocognitive prescreening tests every 3 months using a specialized artificial intelligence-driven platform, allowing them to take detailed memory assessments online from home. Among those prescreened, 18 individuals with lower neurocognitive scores (mean age, approximately 55 years) and 19 cognitively normal control individuals without breast cancer (mean age, approximately 67 years) underwent comprehensive, in-person, neurocognitive evaluations and MRI scans. Researchers analyzed the scans using region of interest (ROI) and voxel-based morphometry (VBM), which uses sophisticated computer software, to assess grey matter volumes and surface areas. The ROI analysis revealed significant reductions in gray matter volume (measured in mm3) and surface area (measured in mm2) among patients experiencing chemobrain, particularly affecting the isthmus cingulate and pars opercularis, with changes extending into the orbitofrontal and temporal regions. Significant Atrophy The VBM analysis confirmed significant atrophy in the frontal, parietal, and cingulate regions of patients with chemobrain compared with control individuals ( P < .05). Edison noted that this pattern overlaps with brain changes typically observed in Alzheimer's disease and vascular cognitive impairment. For both analyses, 'we demonstrated there is some amount of shrinkage in the brain among patients with chemobrain.' he said. 'The fact that controls are older means the results are even more significant as there's more brain atrophy as people age.' Some of the affected brain regions may be linked to impaired memory, a hallmark of Alzheimer's disease, but Edison cautioned that given the small sample size this finding should be interpreted with caution. While the analysis demonstrated overall lower brain volumes in patients with 'chemobrain' compared with controls, Edison emphasized that this finding reflects a single time point and does not indicate brain shrinkage over time. Other events, including stroke — can also cause brain changes. Edison highlighted the importance of determining the significance of these brain changes, how they affect patients and whether they can be prevented. In-person neurocognitive testing revealed significantly reduced semantic and verbal fluency, as well as lower Mini-Mental State Examination scores in patients with chemobrain. Edison noted that these results support the MRI findings. The team plans to follow patients to track brain changes and memory recovery, Kenny said. While patients with breast cancer are a common focus, the researchers intend to expand the study to other cancers in both men and women, said Kenny. Anecdotally, many patients report memory problems during chemotherapy, she added. Based on discussions with her oncology colleagues, Kenny noted that many patients anecdotally report experiencing memory problems during chemotherapy. More Research Needed Commenting for Medscape Medical News , Rebecca M. Edelmayer, PhD, vice president, Scientific Engagement, at the Alzheimer's Association, said the research may help shed light on why women are more likely to develop dementia than men. For years now, experts have been trying to figure out what puts women at higher risk for AD and other dementias, said Edelmayer. 'We still don't understand whether this involves biologically driven risk factors or socially driven risk factors.' Research linking treatments for other health conditions to increased memory problems may offer some clues, she noted, suggesting a potential avenue for further investigation into the intersection of chemotherapy and neurodegenerative diseases such as Alzheimer's. However, Edelmayer emphasized that this line of research is still in its infancy. Much more work is needed to determine whether there is a direct cause-and-effect relationship with specific chemotherapy drugs, and whether some patients may already be predisposed or at higher risk for cognitive decline, she said. Also commenting for Medscape Medical News , Eric Brown, MD, associate scientist and associate chief of geriatric psychiatry at the Centre for Addiction and Mental Health in Toronto, Ontario, Canada, raised concerns about the study's design. One issue, he noted, is that the researchers did not image all patients who received chemotherapy but instead selected those with the most significant cognitive impairment. As a result, the findings may not have reflected outcomes in the average post-chemotherapy patients but rather represent the most severely affected subgroup. Brown also pointed out that the study did not clarify whether this subgroup had comorbid conditions. It's possible, he said, that some individuals may have had Alzheimer's disease or other forms of dementia unrelated to chemotherapy. He agreed that tracking longitudinal changes in both cognitive scores and neuroimaging — comparing patients who receive chemotherapy with those who do not — would be a valuable next step.
